 |
|
|
|
 |
|
|
| Article 1 to 10 out of 15 concerning Cytori Therapeutics, Inc.
|
-
Court Determines that University of Pittsburgh and Artecel Have Sole Rights to Adipose-Derived Stem Cell Patent
(23 Jun 2008)
Artecel, Inc., announced that the patent inventorship litigation concerning the foundational, composition-of-matter patent covering stem cells isolated from adipose (fat) tissue has been decided in favor of Artecel's licensor, the University of ...
-
Adipose-Derived Stem & Regenerative Cells Improve Fat Graft Retention in Preclinical Study
(19 Dec 2007)
Cytori Therapeutics, Inc. reported positive preclinical results demonstrating adipose-derived stem and regenerative cells improved the quality and longterm retention of a fat graft, representing a potential new approach in reconstructive surgery. ...
-
Cytori's Celution System Under Evaluation for Breast Augmentation as Part of Investigator Initiated Study
(08 Nov 2007)
A new study underway in Japan will examine the effect of adult stem and regenerative cells derived from adipose tissue in breast augmentation. In this investigational procedure, a patient's breast is augmented with her own liposuctioned fat, which ...
-
Adipose Stem & Regenerative Cells Not Linked to Arrhythmias in Preclinical Study
(24 Oct 2007)
Important Safety Findings Published in EuroPace Cardiology Journal
Stem and regenerative cells derived from adipose (fat) tissue were found not to be linked to arrhythmias following a heart attack in a preclinical study. The findings were reported in the advance access of EuroPace, a journal of the European Society ...
-
Cytori awarded NIH Grant to develop cell-based treatments for vascular disease
(21 Sep 2007)
Cytori Therapeutics was awarded a $250,000 NIH (National Institutes of Health) Grant to develop adipose-derived regenerative cells as a treatment for vascular disease.Regenerative cells within adipose (fat) tissue include adult stem cells and other ...
-
Cytori Therapeutics to Voluntarily Delist From the Frankfurt Stock Exchange to Consolidate Trading on the NASDAQ Global Market
(28 Jun 2007)
Cytori Therapeutics is voluntarily delisting from the Frankfurt Stock Exchange (FSE). The move is primarily in response to the significant shift in trading volume since December 2005 from the FSE toward the NASDAQ Global Market, where Cytori will ...
-
Invitrogen Partners with Cytori to Offer Adipose Stem Cell Research Products
(10 May 2007)
Invitrogen Corporation and Cytori Therapeutics entered into a global strategic supply and commercialization agreement to offer adipose-derived stem cell-based research products to life science researchers. Invitrogen will offer Cytori's stem cell ...
-
Cytori Forms Stem Cell Therapy Distribution Partnership in Spain, Italy and Portugal
(22 Feb 2007)
Cytori Therapeutics entered into an agreement with MBA Grupo, a European healthcare distributor, who will distribute the Celution(TM) System in Spain, Italy and Portugal starting early 2008 for reconstructive surgery applications. MBA Grupo will ...
-
First Heart Patient Treated in Adipose Stem Cell Trial
(08 Feb 2007)
Cytori's Cardiovascular Stem Cell Study Initiated
Cytori Therapeutics and Hospital Gregorio Maranon in Madrid, Spain treated the first patient in Cytori's randomized clinical trial investigating the safety and feasibility of adipose-derived stem and regenerative cells as a therapy for ...
-
Cytori to Begin Stem Cell Trial for Heart Disease
(05 Jan 2007)
Cytori Therapeutics received approvals to initiate a clinical trial in Spain to investigate the use of adipose-derived stem and regenerative cells for the treatment of cardiovascular disease. The cells will be obtained at the bedside from the ...
Additional information
Cytori Therapeutics, Inc.
San Diego, CA, United States of America
Company
|
|
|
|
|
|
Top
